Table 4.
ASDAS-CRP comparison of cytokines in active-AS group responders and nonresponders after 24 months of TNF blockade, control-AS group, and healthy controls
| Control-AS group | |||||||
|---|---|---|---|---|---|---|---|
| Active-AS patients after anti-TNF | (ASDAS-CRP <2.1; n = 21) | Healthy controls (n = 47) | |||||
| Cytokine | Responders | Nonresponders | p valuea | p valueb | p valuec | ||
| (ASDAS-CRP <2.1; n = 27) | (ASDAS-CRP ≥2.1; n = 20) | ||||||
| IL-17A (pg/ml) | 2.17 (0.86–3.99) | 1.04 (0.66–1.82) | <0.05 | 1.29 (1.10–2.17) | 0.07 | 1.57 (1.04–2.17) | 0.23 |
| IL-22 (ng/ml) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.99 | 0.00 (0.00–0.00) | 0.71 | 0.00 (0.00–0.00) | 0.64 |
| IL-23 (ng/ml) | 0.09 (0.03–0.21) | 0.05 (0.02–0.13) | 0.49 | 0.02 (0.01–0.06) | 0.01 | 0.02 (0.00–0.05) | <0.001 |
| PGE2 (pg/ml) | 13.03 (4.30–56.59) | 45.17 (10.92–93.76) | 0.10 | 8.13 (4.17–23.07) | 0.11 | 7.66 (3.30–30.32) | 0.33 |
All values are expressed as the median (25–75 % interquartile range)
aActive-AS group responders after 24 months of TNF blockade vs. nonresponders
bActive-AS group responders after 24 months of TNF blockade vs. control-AS group (ASDAS-CRP <2.1)
cActive-AS group responders after 24 months of TNF blockade vs. healthy controls
AS ankylosing spondylitis, ASDAS-CRP C-reactive protein Ankylosing Spondylitis Disease Activity Score, IL interleukin, PGE2 prostaglandin E2, TNF tumor necrosis factor